DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the market capitalisation of Transgene Biotek Ltd?

Transgene Biotek Ltd has a market capitalisation of approximately ₹23 crore.

Transgene Biotek Ltd

TRANSGENEBIOTEKLTD·NSE·Healthcare Services

₹0.00▲ +0.00 (+0.00%)

⚠️Trading suspended. Not a live price.

Healthcare Services · Healthcare Service Provider

Carries meaningful debt — watch the balance sheet

52W₹2

₹5-53%

Open

—

High

—

Low

—

Prev Close

—

Volume

—

VWAP

—

Snapshot

Key fundamentals

Market Cap

₹23 Cr

P/E Ratio

N/A

P/B Ratio

2.78

EPS

₹-0.22

Book Value

₹1.11

ROE

-17.90%Weak

ROCE

-2.36%Weak

Dividend Yield

0.00%

Debt / Equity

2.05High

Face Value

₹10.00

52W High

₹5.26

52W Low

₹1.83

Sector

Healthcare Services

Industry

Healthcare Service Provider

Expensive

None moatVery High uncertainty

Fair value estimate

₹1

No recent traded price

BearFair valueBull

₹1₹1₹1

/100

Business quality — Watch the fundamentals

Growth 50Profitability 0Efficiency 0Valuation 0

Plain English

Our view

Carries meaningful debt — watch the balance sheet
High leverage — debt exceeds 1.5× equity

Risks

High leverage — debt exceeds 1.5× equity
Weak returns on equity (-18%)

How we got there

Fair value methods

Residual income

-18% ROE fading to 15% over ~3 yrs, on ₹1 book

₹1

Relative P/E

Needs positive EPS

—

Graham floor

Needs positive EPS

—

Analyst target

No analyst coverage

—

Blended fair value₹1

What the numbers say

Investment thesis

Bull case

No standout positives from the current metrics.

Bear case

High leverage — debt exceeds 1.5× equity
Weak returns on equity (-18%)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

—

ROE

-17.9%Weak

Above 15% is considered healthy for Indian equities

ROCE

-2.4%Weak

Above 18% means capital is working hard

Debt/Eq

2.05High

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹23 Cr

P/B

2.78

EPS

₹-0.22

Div Yield

—

What changed

Recent changes

No notable changes to report.

What matters

News impact

Overview

Valuation

N/A

No P/E

Growth

Strong

+52% rev CAGR

Profitability

Loss-making

-17.9% ROE

Financial health

High debt

D/E 2.05

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover—

Trades—

VWAP—

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+51.8%

+4.3%

10Y

+1.6%

Profit

—

10Y

—

EPS

—

10Y

—

Profile

Cons

Stock is trading at 2.78 times its book value
Company has low interest coverage ratio.
Promoter holding is low: 23.6%
Company has a low return on equity of -9.77% over last 3 years.
Company might be capitalizing the interest cost

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Ownership was broadly stable versus the previous quarter. The QoQ column shows each group's change versus the prior quarter.

24%

Promoter

Promoters

23.6%0.00

Public

71.8%-0.04

FII / FPI

0.0%0.00

DII

0.0%0.00

Others

4.5%

Total shareholders

13,767+222 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter23.64%

Public71.81%

Others4.55%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1990, Transgene Biotek Ltd is in the business of Research & Development[1]